BCR and chronic myelogenous leukemia, BCR-ABL1 positive: For patients with CML‐CP, the deepest levels of response designated as treatment goals by the NCCN and ELN are complete cytogenetic response (CCyR; 0% Philadelphia chromosome [Ph]+ metaphases) and major molecular response (MMR; BCR‐ABL1 transcript ratio ≤0.1% on the International Scale [IS; BCR‐ABL1IS]), respectively 18, 19.